Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of S-1-based chemotherapy with or without nivolumab in locally advanced or borderline resectable pancreatic cancer
jRCT2080225361Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab, tegafur and gemcitabine in pancreatic cancer (PC) (2 arms), sponsored by Ono Pharmaceutical. Started Aug 2020; status: completed.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2080225361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225361.